Sleep Apnea News and Research

RSS

UC San Diego receives grant to study hypoxia susceptibility

Gabriel G. Haddad, MD, chair of the Department of Pediatrics at the University of California, San Diego School of Medicine and Physician-in-Chief at Rady Children's Hospital-San Diego has received a $10 million grant from the National Institute of Health's Heart, Lung and Blood Institute.

24 Sep 2010

ImThera Medical releases interim results of clinical study on neurostimulation device for treating OSA

ImThera Medical, Inc. today announced interim results from its OSA European clinical study. For the study, ten patients have been surgically implanted with ImThera's aura6000 hypoglossal nerve neurostimulation device for treating Obstructive Sleep Apnea. The target population for ImThera's neurostimulation device is moderate and severe OSA patients who are non-compliant with or cannot tolerate Continuous Positive Airway Pressure.

22 Sep 2010

VIVUS announces QNEXA study results for obesity treatment

VIVUS, Inc. today announced positive top-line results from a two-year study of QNEXA(phentermine/topiramate) Controlled Release Capsules, an investigational therapy for treatment of obesity, a condition that affects approximately one-third of adult Americans.

21 Sep 2010

Bruner to encourage FDA advisory committee to consider effectiveness of obesity drug Lorcaserin

On September 16, Denise Bruner, MD, FASBP will speak in favor of FDA approval for the new obesity drug Lorcaserin, during the open public hearing hour at the Endocrinologic and Metabolic Drug Advisory Committee meeting.

15 Sep 2010

Somaxon's Silenor now commercially available in U.S.

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that Silenor® (doxepin) now is commercially available by prescription in the United States. Somaxon has implemented a wholesale and retail stocking program to disseminate Silenor 3 mg and 6 mg dosepacks to pharmacies across the United States. Silenor is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

7 Sep 2010

Chronic insomnia with objectively measured short sleep duration associated with increased mortality in men

A study in the Sept. 1 issue of the journal SLEEP found an elevated risk of death in men with a complaint of chronic insomnia and an objectively measured short sleep duration. The results suggest that public health policy should emphasize the diagnosis and appropriate treatment of chronic insomnia.

2 Sep 2010

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.

31 Aug 2010

Victhom second-quarter revenues decrease 94.4% to $27,901

Victhom Human Bionics Inc. today reported its second quarter 2010 financial results.

27 Aug 2010

Exmovere to release vital sign monitoring infant sleepwear

Exmovere Holdings, Inc., a biomedical engineering company, today announced plans to release vital sign monitoring infant sleepwear. Exmovere is in the advanced stages of taking to market a washable, conductive fabric-based biosensor pajama called "Exmobaby." Exmobaby is the first-ever baby garment developed for remote monitoring of heart rate, emotional state and behavior.

27 Aug 2010

Researchers recommend traumatic brain injury reclassification for additional funding

Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston.

27 Aug 2010

Somaxon Pharmaceuticals, Procter & Gamble to co-promote Silenor

Somaxon Pharmaceuticals, Inc. today announced that Somaxon and Procter & Gamble have entered into a co-promotion agreement for Silenor (doxepin), a newly-approved treatment for insomnia characterized by difficulty with sleep maintenance.

25 Aug 2010

Cortex second-quarter net loss decreases to $0.04 per share

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $2,454,000, or $0.04 per share, for the quarter ended June 30, 2010, compared with a net loss applicable to common stock of approximately $2,778,000, or $0.06 per share, for the corresponding prior year period.

16 Aug 2010

Obesity linked to sleep disorders: Study

Specialists at a sleep clinic in Newcastle, Australia have analyzed 20 years of patient’s records and found that their patients are becoming increasingly obese. This means that the rise in obesity rates is directly related to rise in sleep problems they say.

16 Aug 2010

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Graymark Healthcare, Inc. today announced financial results for the quarter ending June 30, 2010 including $1.1MM of EBITDA on $28.3MM in sales.

10 Aug 2010

Endo to acquire Penwest for $5.00 per share

Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.

10 Aug 2010

ResMed revenue increases 16% to $291.6 million for quarter ended June 30, 2010

ResMed Inc. today announced record revenue and income for the quarter ended June 30, 2010, and a two-for-one stock split.

From ResMed Corp 6 Aug 2010

Rotech Healthcare second-quarter adjusted EBITDA increases to $29.2 million

Rotech Healthcare Inc. today announced financial results for the three and six months ended June 30, 2010.

5 Aug 2010

VIVUS second-quarter total revenue decreases to $3.9 million

VIVUS, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter and six months ended June 30, 2010.

3 Aug 2010

Graymark Healthcare adds two new sleep centers in Texas, Nebraska

Graymark Healthcare announced that it has added two new sleep centers in Texas and Nebraska with the signing of agreements to provide on-site services to Goodall-Witcher Medical Center in Central Texas and Henderson Community Hospital in Nebraska. These agreements continue to execute on Graymark's strategy to expand the availability of sleep medicine in rural communities that otherwise might not have access to comprehensive sleep care.

30 Jul 2010

Four areas that impact weight, obesity in women identified

The information gap and general lack of understanding of obesity's unique and disproportionate impact on women contributes to the challenges of the 65 million American women who are considered overweight or obese, said the Strategies to Overcome and Prevent (STOP) Obesity Alliance Task Force on Women at a meeting on Capitol Hill today.

22 Jul 2010